cheers, if we associate value with partnerships the clear focus needs to be in FTO and cardio protect arena.
We have the cardio protect, melanoma and AML P2 later in the year would be good to collaborate with a drug supply agreement.
I think timing of this is sooner rather than later as clinical trial input and dosing etc would need to be carefully designed now and not once P2 kicks off!
How soon, not to sure but perhaps pre oppy expiry in May!
General Comments / Chat, page-5428
-
- There are more pages in this discussion • 5,801 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
-0.055(3.31%) |
Mkt cap ! $273.4M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.68 | $1.61 | $271.5K | 166.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1996 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.68 | 1305 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |